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In vitro downregulated hypoxia
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Abstract
Background: Hypoxia is a characteristic of breast tumours indicating poor prognosis. Based on the assumption that
those genes which are up-regulated under hypoxia in cell-lines are expected to be predictors of poor prognosis in
clinical data, many signatures of poor prognosis were identified. However, it was observed that cell line data do not
always concur with clinical data, and therefore conclusions from cell line analysis should be considered with caution.
As many transcriptomic cell-line datasets from hypoxia related contexts are available, integrative approaches which
investigate these datasets collectively, while not ignoring clinical data, are required.
Results: We analyse sixteen heterogeneous breast cancer cell-line transcriptomic datasets in hypoxia-related conditions
collectively by employing the unique capabilities of the method, UNCLES, which integrates clustering results from
multiple datasets and can address questions that cannot be answered by existing methods. This has been demonstrated
by comparison with the state-of-the-art iCluster method. From this collection of genome-wide datasets include 15,588
genes, UNCLES identified a relatively high number of genes (>1000 overall) which are consistently co-regulated over all
of the datasets, and some of which are still poorly understood and represent new potential HIF targets, such as RSBN1
and KIAA0195. Two main, anti-correlated, clusters were identified; the first is enriched with MYC targets participating in
growth and proliferation, while the other is enriched with HIF targets directly participating in the hypoxia response.
Surprisingly, in six clinical datasets, some sub-clusters of growth genes are found consistently positively correlated
with hypoxia response genes, unlike the observation in cell lines. Moreover, the ability to predict bad prognosis
by a combined signature of one sub-cluster of growth genes and one sub-cluster of hypoxia-induced genes appears
to be comparable and perhaps greater than that of known hypoxia signatures.
Conclusions: We present a clustering approach suitable to integrate data from diverse experimental set-ups. Its
application to breast cancer cell line datasets reveals new hypoxia-regulated signatures of genes which behave
differently when in vitro (cell-line) data is compared with in vivo (clinical) data, and are of a prognostic value comparable
or exceeding the state-of-the-art hypoxia signatures.
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Background
Hypoxia, that is reduced levels of oxygen, is a character-
istic of solid tumours, including breast cancer, as a result
of poor vascularisation, increased metabolism, and high
proliferative rates [1, 2]. Amongst the different breast
cancer subtypes, triple-negative breast cancer (TNBC,
estrogen, progesterone and HER2 negative) is the one
most frequently associated with hypoxia [3, 4]. More-
over, hypoxia is associated with increased metastasis and
resistance to chemotherapy and radiotherapy, leading to
poorer rates of survival [5]. These observations indicate
why the gene expression signature of breast cancer
tumours under hypoxia has a prognostic value, and also
the reasons that hypoxia is a key area for the development
of targeted therapy [5–8].
As a response to hypoxia, transcriptional programmes
are induced in tumour cells that produce resistance to
the stress of the low-oxygen micro-environment. This
hypoxia response is mediated by the stabilisation of the
hypoxia inducible factor (HIF) proteins, which transcrip-
tionally activate over 300 genes [2, 9]. The HIF complex
is a heterodimer composed of an alpha subunit and a
beta subunit [9–11]. Three different HIFα proteins are
known, namely the ones encoded by HIF1α, HIF2α
(EPAS1), and HIF3α, while the HIFβ subunit is encoded
by ARNT [12]. However, the role of HIF1α and HIF2α is
relatively more understood in this process than HIF3α
[12]. Normal levels of oxygen provide an essential co-
factor for prolyl hydroxylases to hydroxylate HIF1 and
2α. This marks them for degradation by the proteasome
after being ubiquitinated by Von-Hippel Lindau (VHL)
syndrome protein. Thus abundance of oxygen represents
a signal for the degradation of HIF while hypoxia results
in its stabilisation [9–11, 13].
HIF heterodimers bind to the hypoxia response
element (HRE) motif, with the consensus sequence of
RCGTG, at the promotors of many genes resulting in
their transcriptional activation [2, 14]. These genes
participate in key biological processes, such as angio-
genesis, pH regulation, metabolism, autophagy, inva-
sion, metastasis, and others, which promote tumour
growth [2, 13, 15–18].
Targeting HIF directly has proven to be difficult [19].
However, genes activated by HIF under hypoxia, such as
the key angiogenesis regulator VEGF, or the unfolded
protein response, mediated by factors like XBP1 and
ATF4, can be targeted [8, 20–23]. So far there has been a
larger focus on genes transcriptionally activated by HIFs.
However, many genes are downregulated in hypoxia indir-
ectly regulated by HIF [24, 25], which could provide op-
portunities for synthetic lethality. Therefore, we have
conducted an analysis extending a recently published con-
sensus clustering method [26] and using all available
experiments exposing breast cell lines to hypoxia and
hypoxia related treatments, using different setups and
timing. The power of our clustering approach is that it
allows us to analyse these datasets collectively, to define
genes consistently co-expressed in hypoxia, upregulated
and downregulated, and the potential mechanisms of their
regulation.
Results and analysis
Cell-line datasets & experimental procedures
We considered a comprehensive series of sixteen human
breast cancer cell-line microarray datasets, covering
different breast cancer subtypes, and testing the hypoxia
response using different experimental setups (Table 1).
The first column shows the unique name which is used
hereinafter to refer to each of these datasets. Due to the
differences in the microarray platforms used to generate
these datasets, not all genes are represented by probes in
all of the datasets. However, 15,588 genes were found in
common in at least thirteen out of the sixteen datasets,
and they represent the input set of genes to the following
analysis. These genes are listed in Additional file 1.
An important generalisation was made to UNCLES
type A method [26, 27] in order to enable its use to
cases where missing features are present (see Methods).
In particular, the extended UNCLES allows inclusion of
genes which are represented by probes in some rather
than all datasets analysed. Had the condition of gene in-
clusion been as required by the original UNCLES
method, described in [26], only 7714 genes would have
been considered in this analysis, which is less than 50%
of the array content. Therefore, this modification allows
for more comprehensive analysis of available datasets
and reduces the amount of data filtered out due to missing
data or less complete platforms.
The UNCLES method does not perform its collective
analysis to such group of heterogeneous datasets by
merging them into a single dataset; rather it clusters
each one of them individually by multiple clustering
methods, and then finds the consensus result of these
individual clustering results. In other words, UNCLES
finds the consensus membership of genes in clusters
based on results from independent clustering analyses of
multiple datasets rather than merging the datasets them-
selves. This approach overcomes the problems that
appear while attempting merging datasets generated by
different platforms and with different conditions. This is
detailed in the Methods section and in [26, 27].
Individual clustering methods employed at the first step
of the UNCLES method were k-means with Kauffman
initialisation (KA), self-organising maps (SOM) with bub-
ble neighbourhood and four-by-four grid, and hierarchical
clustering (HC) with Ward’s linkage. The experiment was
repeated with the numbers of clusters (K values) of 8, 9,
10, 16, 18, 24, 30, and 40, and while varying the tuning
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parameter δ from zero to unity with steps of 0.1. The
resulting clusters from all of these experiments were
exposed to the M-N scatter plots [26] in order to select
the top clusters (see Methods).
Consensus clustering identifies two clusters of genes
oppositely co-regulated under hypoxia across 16 diverse
cell-line datasets
As explained in Methods, the M-N scatter plots tech-
nique is used to select the best clusters out of the pool
of clusters generated under different K and δ values.
This selection is done sequentially in a descendant order
of the quality of the selected clusters and the quality
measure is the distance of the cluster from the top-left
corner of the M-N plot. This metric should be mini-
mised, i.e. lower values of it indicate better clusters in
quality. The M-N distances of the first ten clusters,
labelled as C1 to C10, are plotted in Fig. 1. This Figure
shows that the first two clusters have significantly lower
distances, and thus better quality, than the rest of the
Table 1 Breast cancer microarray datasets in contexts related to hypoxia
ID GEO acc. Year Platform acc. Platform Nb Cell line(s) Description Ref.
D01 GSE3188a 2005 GPL2507 Sentrix Human-6 7 MCF7 Same samples of the last two datasets in
the same order, but a different platform.
[67]
D02 GSE47533 2014 GPL6884 Illumina HumanWG-6 v3.0 4 MCF7 Time-series data through 48 h of exposure
to hypoxia (1% O)
[40]
D03 GSE41491 2012 GPL14877 Affymetrix HG-U133+ 2.0 8 MCF7 Time-series data through 24 h of exposure
to hypoxia (1% O)
[68]
D04 GSE47009 2014 GPL16686 Affymetrix HuGene 2.0 ST 3 MCF7 Samples at normoxia, hypoxia, and anoxia,
respectively
-
D05 GSE18494 2009 GPL9419 Affymetrix HG-U133+ 2.0 4 MDA-MB-231 Time-series data through 12 h of exposure
to hypoxia (0.5% O)
[43]
D06 GSE3188a 2005 GPL96 Affymetrix HG-U133A 3 MCF7 Samples at normoxia, hypoxia, and normoxia
exposed to DMOG, respectively
[67]




Time-series data through 24 h of exposure
to hypoxia.
[69]
D08 GSE17188a 2010 GPL6480 Agilent Whole Human
Genome G4112F
3 LM2 subline of
MDA-MB-231
Time-series data through 24 h of exposure
to hypoxia.
[69]
D09 GSE15530 2010 GPL6947 Illumina HumanHT-12 V3.0 4 MCF7 Normoxia samples versus hypoxia samples,
each is either transfected with non-specific
shRNA or with reptin shRNA.
[28]
D10 GSE45362 2013 GPL10558 Illumina HumanHT-12 V4.0 4 MB231RN-LM derived
from MDA-MB-231
Non-transfected samples versus transfected
with has-miR-18a, each is in either a control
medium or treated with Cobalt(II) chloride
(CoCl2) hypoxia-mimicking agent.
[70]
D11 GSE29406 2012 GPL571 Affymetrix HG-U133A 2.0 4 MCF7 Normoxia samples versus hypoxia samples,
each is either untreated or treated with
lactic acid.
[71]
D12 GSE18384 2010 GPL6884 Illumina HumanWG-6 v3.0 4 MCF7 Normoxia samples versus hypoxia samples,
each is either non-transfected or transfected
with siRNA#1 against JMJD2B
[72]
D13 GSE3188a 2005 GPL570 Affymetrix HG-U133+ 2.0 4 MCF7 Samples exposed to / transfected with
oligogectamine, HIF1α siRNA, HIF2α siRNA,
or both siRNAs, respectively. All samples
were grown under hypoxia (1% O) for 16 h.
[67]
D14 GSE33438 2011 GPL1708 Agilent Whole Human
Genome G4112A
4 MCF7 & ZR-75-1 Samples from each of the two cell lines
were exposed to hypoxia for 24 h or 48 h
[73]
D15 GSE49953 2013 GPL570 Affymetrix HG-U133+ 2.0 4 T47D & MDA-MB-231 A control sample and an XBP1-knocked-down
sample from each of the two cell lines. All
samples are under hypoxia and glucose
deprivation.
[74]
D16 GSE30019 2012 GPL6884 Illumina HumanWG-6 v3.0 6 MCF7 Time-series data through 24 h of
reoxygenation after having been in
hypoxia (0.5% O) for 24 h.
[75]
aSome accession numbers refer to datasets which include samples that in reality represent more than one dataset, either because they belong to different
microarray platforms or to different cell lines
bThis is either the number of time-points in time-series data or the number of conditions in other types of data
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clusters. Therefore, these two clusters were chosen for
the following investigations.
The first cluster, C1, includes 504 genes, while the sec-
ond cluster, C2, includes 598 genes. Full lists of genes in
these two clusters are provided in Additional file 1 and
the average expression profiles of these two clusters in
each of the sixteen datasets are plotted in Fig. 2. A
fully labelled version of this Figure is provided in
Additional file 2. Interestingly, it is notable in Fig. 2
that the profiles of the two clusters are consistently
negatively correlated in all of the datasets. Also, the
first cluster is downregulated with hypoxia while the
second is upregulated in general.
In order to measure the negative correlation be-
tween C1 and C2 quantitatively, Pearson’s correlation
(ρ) was calculated between their average profiles in
each of the 16 datasets and is shown in Fig. 3. The
correlation between the two clusters does not exceed
the very low value of −0.95 in any of the datasets
except for D1 (ρ = −0.87), D10 (ρ = −0.89), and D14
(ρ = −0.89). This very strong and consistent negative
correlation, with no phase-shift, over sixteen different
datasets from a wide range of experiments suggests
that these two clusters may be oppositely co-regulated
by a common mechanism.
D02, D03, D05, D07, and D08 represent time-series
datasets in which breast cancer cell lines were ex-
posed to hypoxia for durations ranging from 12 to
48 h (Table 1). The first time-point in each of them
is at normoxia, or in other words, at zero hours after
exposure to hypoxia. It can be seen that, in all of
these cases, C1 is downregulated gradually in hypoxic
conditions while C2 is upregulated (Fig. 2). In con-
trast, the dataset D16 represents time-series through
reoxygenation, i.e., the first time-point is at hypoxia
(0.5% Oxygen), followed by shifting the cells back to
normal oxygen levels (21%) and observing their gen-
etic expression for 24 h following the shift (Table 1).
Agreeing with the previous observation, C1 shows
gradual upregulation under reoxygenation while C2
shows gradual downregulation (Fig. 2).
Similar observations can be seen in the other data-
sets while comparing normoxic with hypoxic condi-
tions (Fig. 2 and Additional file 2). In some datasets,
exposure to some agents mimics the effect of real hypoxia,
such as exposure to 2-oxoglutarate dependent dioxy-
genase inhibitor dimethyloxalylglycine (DMOG) (D01 and
D06), and to CoCl2 (D10). Similarly, normoxic effects
were observed in some datasets in cell lines under hypoxia
when certain hypoxia-negating modifications were ap-
plied; examples include transplanting with has-miRNA-



































Fig. 1 M-N scatter plots’ distances. Quality evaluation of the first ten
clusters selected by the M-N scatter plots technique. Quality is quantified
by the M-N distance metric, which has smaller values for better clusters.
The M-N plots technique inherently orders the clusters that it
selects from the best to the worst. In this Figure, it is clear that the
first two clusters have significantly smaller M-N distance values than
the rest, and therefore they are labelled as “good clusters” and are

































Time / Conditions Time / Conditions
       C2
(598 genes)
       C1
(504 genes)
Fig. 2 Clusters average profiles over datasets. The average profiles of
the clusters C1 and C2 in each of the 16 datasets (D01 to D16). The
two columns of plots correspond to the two clusters while the 16
rows correspond to the 16 datasets. The plots are scaled horizontally
to reflect the number of data points (time/conditions) that each
dataset has (ranging from 3 in D04, D06, D07 and D08 to 7 in D01).
A detailed version of this Figure is included in Additional file 2
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18a (D10), treatment with lactic acid (D11), and knocking
down key regulators of hypoxia such as HIF1A (D01 and
D13) and XBP1 (D15).
However, some treatments which were expected to re-
duce the effect of hypoxia were not observed to have an
effect on these two clusters. For instance, transfection
with reptin siRNA in D09 or knocking down HIF2A in
D01 or D13 did not show a significant reduction in the
effects of hypoxia. As for reptin, it was previously shown
that about 25% of genes up- or down-regulated by hyp-
oxia are reptin-dependant while the rest are not [28].
The clusters C1 and C2 are significantly enriched with
reptin-independent hypoxia-regulated genes (p-values:
1.7 × 10−23 and 1.2 × 10−22 for C1 and C2 respectively)
but are not as significantly enriched with reptin-
dependent genes (p-values: 6.5 × 10−3 and 6.6 × 10−3 for
C1 and C2 respectively); this indeed justifies our obser-
vation here. As for knocking down HIF2A, it was in
comparison with knocking down HIF1A, and it is clear
that these two clusters have dependency on HIF1A ra-
ther than on HIF2A. Despite that, knocking down
HIF1A could not fully restore the expression of these
two clusters to the same level as in normoxia (D01).
Clusters of co-regulated genes map to distinct pathways,
biological processes and cellular components
We have performed GO term analysis over the genes in
C1 and C2 to identify the most significantly enriched
biological processes and cellular components in them
using the GeneCodis online tool [29–31]. Full lists of re-
sults are available in Additional files 3 and 4 for C1 and
C2 respectively.
Analysis of C1 GO terms revealed four major groups
of genes participating in specific biological processes
with significant localisation in the nucleolus, the nucleo-
plasm, the mitochondrion, or the cytosol. Those are
summarised in Fig. 4.
The general characteristic of C1 is that it is highly
enriched with genes participating in growth-related pro-
cesses such as the mitotic cell-cycle, gene expression (e.g.
RNA metabolic process and RNA splicing), and protein
synthesis (e.g. translation, ribosome biogenesis, rRNA pro-
cessing, tRNA processing, and protein folding).
The localisation of the genes participating in these
processes highlights rRNA processing and ribosome
biogenesis (aka RRB) genes in the nucleolus; mitotic
cell-cycle, RNA metabolism, and RNA splicing in the
nucleoplasm; genes participating in mitochondrial pro-
tein translation localise, clearly, in the mitochondrion;
and some cell-cycle, RNA metabolism, and protein fold-
ing genes localised in the cytosol. These observations
can be summarised as four groups of growth-related pro-
cesses which take place in four different locations of the
cell are down-regulated simultaneously by hypoxia. Thus
there is a major suppression of processes that use high
amounts of ATP, potentially contributing to cell survival.
C2, which is upregulated under hypoxic conditions, is
enriched with many genes well described as part of the
hypoxia transcriptome and are HIF targets (Table 2).
These genes include those involved in signal transduction
[32], positive regulation of I-kappaB kinase/NF-kappaB
cascade [33], carbohydrate metabolism and glycolysis
[34–38], chromatin remodelling [39], inhibition of cell
proliferation [17] (Table 2). Also, C2 included a large
number of genes which participate in regulation of
DNA transcription, whether that was in the form of tran-
scription factors, chromatin organisation, or otherwise
(Table 2).
As for the cellular components in which C2 genes local-
ise, in addition to nuclear and cytoplasmic genes,

















Fig. 4 The localisation of the biological processes of the genes in
C1. The Figure shows the numbers of genes included in C1 which
localise into the cytosol, mitochondrion, nucleolus, and the
nucleoplasm, as well as the main biological processes which are
enriched in each one of these sub-cellular components





















Pearson's correlation ( ) between
average expression profiles of C1 and C2
in each one of the datasets D01 to D16
 = -0.85
 = -0.95
Fig. 3 Correlation between C1 and C2. Pearson’s correlation (ρ)
between the average profiles of C1 and C2 in each of the 16 datasets
D01 to D16. Two dashed horizontal lines are shown at ρ = −0.85 and
ρ = −0.95. The two clusters are clearly negatively correlated in all
datasets as their correlation values never exceed −0.95 except in three
datasets, which in their turn are still below ρ = −0.85
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represents a Venn diagram showing the numbers of genes
which belong to the two GO terms ‘membrane’ and
‘plasma membrane’. Also, significant numbers of C2 genes
localise to the Golgi apparatus and the endoplasmic
reticulum, as highlighted in Table 2.
The distribution of genes participating in different
processes over those different cellular components in C2
is not as distinct as was shown in C1 (Fig. 4). In sum-
mary, the C2 genes responding to hypoxia have roles
throughout the cell, such as regulation of transcription
and chromatin remodelling in the nucleus, the activation
of carbohydrate metabolism, including glycolysis, and
signalling.
KEGG pathway analysis were performed by using the
GeneCodis online tool in order to identify the pathways
with genes over represented in the clusters C1 and C2
[29–31]. Full results can be found in Additional files
3 and 4 for the clusters C1 and C2, respectively. The
results of this analysis shows agreement with the re-
sults of the GO term analysis. For instance, C1 is
highly enriched with various growth-related and cell-cycle
pathways such as RNA transport, ribosome biogenesis,
pyrimidine and purine metabolism, spliceosome, cell-
cycle, folate biosynthesis, and RNA polymerase; all are
with corrected p-values lower than 1 × 10−4. Additionally,
the proteasome pathway is strongly correlated, corrected
p-value (1.1 × 10−8).
As for C2, which is up-regulated under hypoxia,
carbohydrate metabolism pathways, namely glycolysis
and the metabolism of fructose, mannose, amino sugars,
starch, sucrose, and pentose phosphate, have corrected
p-values lower than 1 × 10−3. Importantly, the renal cell
carcinoma pathway is also significantly represented in
the cluster with a corrected p-value of 1.8 × 10−4. This
pathway includes genes that are regulated by the HIF
transcription factor, which is stabilised by the mutations
of VHL which are typical of this cancer type. Nine genes
from the cluster C2 are listed as members of this path-
way, BRAF, EGLN1, EGLN3, GAB1, MAP2K1, MET,
SLC2A1, VEGFA, and VEGFC. As for the 14 genes
which are assigned by the GO term analysis to the GO
process term ‘response to hypoxia’, they overlap with the
aforementioned nine genes, but they do not include all
of them. The 14 genes are ALDOC, ANGPTL4, BNIP3,
CITED2, EGLN1, EGLN3, LONP1, NOL3, PAM,
PLOD1, PLOD2, SCNN1B, TH, and VEGFA. As can be
seen, only three genes are in the intersection of the two
groups of genes, while the union of them includes 20
distinct genes. Again, the general observation here is
that KEGG pathway analysis agrees with the GO term
Table 2 Highly enriched cellular processes’ and components’
GO terms in C2 (598 genes)




1609 80 4.4 × 10−14
Glycolysis 45 12 5.6 × 10−9
Carbohydrate metabolic process 290 23 7.3 × 10−7
Signal transduction 1176 51 8.2 × 10−7
Cell cycle 435 25 4.9 × 10−5
Response to hypoxia 175 14 4.2 × 10−4
Chromatin modification 224 15 1.5 × 10−3
Negative regulation of cell
proliferation
341 18 4.3 × 10−3
Multicellular organismal
development
945 33 9.3 × 10−3
Positive regulation of IκB
kinase/NFκB cascade
140 10 9.9 × 10−3
Cellular components
Nucleus 5441 230 4.1 × 10−39
Cytoplasm 5302 218 6.5 × 10−35
Cytosol 2146 93 4.0 × 10−14
Membrane 4065 135 4.3 × 10−12
Golgi apparatus 958 44 3.8 × 10−7
Endoplasmic reticulum 1000 45 4.0 × 10−7
Nucleoplasm 891 38 2.0 × 10−5
Plasma membrane 3575 101 2.5 × 10−5
Integral to membrane 4400 118 3.1 × 10−5
Golgi membrane 420 23 4.9 × 10−5
Endosome 280 18 6.7 × 10−5
The first column shows the GO term, the second column shows the
background frequency, i.e. the number of genes belonging to this GO term
amongst the 34,208 background genes in the Genecodis database, the third
column shows the number of genes belonging to this term amongst the










Fig. 5 Venn diagram of C2 genes belonging to two major membrane-
related GO terms. The two membrane-related GO terms in this
diagram are ‘membrane’, which includes 135 genes and ‘plasma
membrane’, which includes 101 genes. The number of genes in
the union of the two sets is 213 genes. The large rectangle represents
all of the genes in C2, which are 598 genes. The space within the
rectangle but outside all of the circle represents genes included in C2
but not included in any of the two circles, and this includes 385 genes
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analysis in identifying carbohydrate metabolism and re-
sponse to hypoxia/HIF targets as the main groups in C2.
However this also shows the current deficits in the
deposited pathways resulting in discordance between
databases and indicting the need for more comprehen-
sive approaches and multiple genes for any likely utility
in tumour hypoxia classification.
Analysis of HIF targets confirms significant differences
amongst upregulated genes and downregulated genes in
response to hypoxia
Hypoxia-inducible factor (HIF) is a master regulator of
gene expression in response to hypoxia [40]. Therefore,
we have analysed the contents of the cluster C2 in light
of five studies which produced lists of potential targets
for HIF [12, 25, 41–43]. Those five studies produced in
total seven lists of potential HIF targets as some of them
produced separate lists for HIF1α and HIF2α. The seven
lists, labelled as L1 to L7, are described in Table 3.
Strikingly, the union of all of those lists includes 1521
genes, of which 1172 were identified by our analysis,
while the intersection includes two genes only, namely,
RSBN1 and PPP1R3C (Table 4). This is expected due
the wide difference in the experimental approaches.
Interestingly, C2 is significantly enriched with such HIF
target genes (145 out of 598 C2 genes) with a p-value
of 1.2 × 10−38. A conservative analysis of the very tight
intersection of all lists (two genes only) showed one of
the two genes, RSBN1, still overlapping with C2. On
the other hand, C1 is not significantly enriched with
HIF targets.
The 15 genes in C2 which appear in at least five lists
of HIF targets include genes which are well-known par-
ticipants in response to hypoxia processes together with
less well-understood genes, where according to GO term
annotation, there is no specific biological process in
which they are known to participate or a molecular
function which they are known to perform (KIAA0195
and RSBN1). Amazingly, RSBN1 is one of the two only
genes over which there is a consensus amongst all of the
seven lists as a potential HIF target, not previously reported
to be induced by hypoxia, and supposedly exclusive to sper-
matids. This is further discussed in the Discussion section.
Cell-line-derived clusters are not conserved in clinical
datasets, but form sub-clusters of highly correlated genes
with distinct biological functions
Having obtained C1 and C2 by clustering gene expres-
sion in cell lines, we investigated their expression in
breast cancer clinical tumours. The Cancer Genome
Atlas (TCGA) is a comprehensive resource for high-
throughput molecular biological data regarding cancers,
and analysed expression profiles in 1026 breast cancer
tumours [44]. This data measures the expression of
20,531 genes in those 1026 samples, and covers 14,493
genes out of the 15,588 genes included in our study
(Additional file 5). In cell lines the cluster C1 contains
504 genes; 471 of these genes are represented and
expressed in this clinical dataset. Similarly, the cluster
C2 in cell lines contains 598 genes; 564 of these genes
are represented and expressed in this clinical dataset
(Additional file 6).
Then, we calculated the pairwise Spearman’s autocor-
relation amongst the genes which belong to each cluster,
C1 and C2, in the 1026 tumours. After applying hier-
archical clustering, the results are shown in the form of
heat maps in Fig. 6. C1 genes form two tight sub-
clusters, labelled as C1a and C1b, which include 116 and
273 genes respectively. Similarly, C2 genes form three
tight sub-clusters, namely C2a, C2b, and C2c, including
204, 88, and 168 genes respectively. The lists of genes in
those sub-clusters are provided in Additional file 5.
We tested whether these sub-clusters also form tight
clusters in other clinical datasets and Table 5 lists the
details of six clinical datasets including the analysed
TCGA dataset. For each sub-cluster, the mean-square
error (MSE) has been calculated in each one of the six
datasets as well as for 1000 randomly generated clusters
of a similar size. By fitting a normal distribution to the
MSE values of the randomly generated clusters, a p-value
Table 3 Description of seven lists of genes which were identified as potential targets for HIF
List TF N Approach Reference
L1 HIF1α 500 Integrative genomes (computational & experimental) [41]
L2 HIF1α 394 Genome-wide ChIP [25]
L3 HIF2α 131 Genome-wide ChIP [25]
L4 HIF1α 311 ChIP-chip [43]
L5 HIF 216 Genome-wide computational approaches [12]
L6 HIF1α 323 ChIP-seq. [42]
L7 HIF2α 268 ChIP-seq. [42]
The first column shows the ID of the list, the second column shows the HIF TF which was considered in the study, the third column shows the number of distinct
genes included in the list (N), the fourth column states the approach adopted to produce the list, and the fifth column shows the reference including the name of
the first author and the year
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has been calculated for obtaining the observed MSE value,
or a more favourable one, randomly. The results revealed
that the sub-clusters C1a, C1b, C2a, and C2b form signifi-
cantly tight clusters in all six datasets with p-values
ranging from 10−6 to smaller than 10−300. On the other
hand, the complete cluster C2 shows relatively poor tight-
ness in the clinical datasets compared to its sub-clusters
with p-values ranging from 0.99 to 10−6 in all data-
sets except for the METABRIC-disc dataset in which
the p-value of C2 is about 10−31. Nonetheless, it is
still not as significantly correlated in that dataset as
C1a, C1b, C2a, and C2b as they all have p-values
smaller than 10−290 therein.
GO term analysis (using the GeneCodis tool [29–31])
was employed to identify any specific enrichment of
biological processes in those sub-clusters. Full results
are shown in Additional file 5. Both C1 sub-clusters
(C1a and C1b) have significant shares of the mitotic
cell-cycle genes. Nonetheless, C1b is specifically highly
enriched with translation, RNA metabolism, gene
expression, protein folding, rRNA processing and
ribosome biogenesis (RRB), and regulation of apop-
totic process, all with corrected p-values lower than
10−5 in C1b and higher than 10−3 in C1a; such differ-
ences in p-values between the two sub-clusters
demonstrate the specificity of enrichment of these
processes in C1b.
Table 4 Different combinations of the seven lists of HIF potential targets
Combination N In this study C1 p.v. C2 p.v. Comments
Union of all 1521 1172 42 0.26 145 1.2 × 10−38 -
Intersection of all 2 2 0 1 7.5 × 10−2 Gene RSBN1 in (C2)
Intersection of studies with
HIF1α (L1, L2, L4, L5, and L6)
11 10 0 6 5.7 × 10−7 Genes in (C2): CA9, DARS, GAPDH, PLOD2,
RSBN1, and SPRY1
In 3 lists or more 144 126 0 61 1.2 × 10−52 -
In 4 lists or more 60 49 0 30 1.5 × 10−30 -
In 5 lists or more 28 22 0 15 6.4 × 10−17 Genes in (C2): CA9, DARS, ENO1, GAPDH, GBE1,
HK2, INHA, INSIG2, KIAA0195, P4HA1, PLOD2,
RSBN1, SPRY1, STC2, WSB1
The first column describes the combination of the lists, the second column shows the number of genes in the combination, the third column shows the number
of those genes which are included in the input 15,588 genes in our study, the fourth and the fifth columns show the numbers of those genes which are included
in C1 and C2, respectively, with their p-values, and the last column shows some comments
a
b
Fig. 6 C1 and C2 form smaller sub-clusters of genes in the TCGA
clinical dataset. Spearman’s autocorrelation amongst the genes in
a C1 and b C2 over the 1026 breast tumour samples provided by
the TCGA database. Indexing of the rows starts from top to bottom
and for the columns starts from right to left, i.e. the first gene is
represented by the top-most row and the right-most column. Colours
in the heat map range from dark brown for +1.0 to dark blue for −1.0.
Sub-clusters of genes based on this autocorrelation are labelled to the
right of the heat maps and white lines are drawn over the heat maps
to highlight their borders






TCGA 1026 YES [44]
GE 196 NO [76]
GSE2034 286 YES [77]
GSE3494 251 YES [78]
METABRIC-disc 997 YES [79]
METABRIC-val 995 YES [79]
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The distinction amongst the three C2 sub-clusters is
more apparent; hypoxia response is focused in the smal-
lest of the three sub-clusters, namely C2b, which also in-
cludes some glucose metabolism and signal transduction
genes; all with corrected p-values lower than 0.01. As for
C2a, the only process which is significantly enriched in
it is the regulation of DNA-templated transcription, with
a corrected p-value of 8.4 × 10−10; no other process is
enriched herein with a corrected p-value lower than
0.01. Interestingly, the two other clusters do not have
this process significantly enriched despite it being the
most enriched process in the mother cluster C2. As for
C2c, it is enriched with many carbohydrate metabolism
(including glycolysis) and signal transduction genes. This
shows that, while each one of the two clusters is consist-
ently co-expressed over 16 different breast cancer cell
line datasets related to hypoxia, they form finer sub-
clusters in real clinical data.
Transcription factor analysis reveals multiple potential
mechanisms of regulation for gene sub-clusters
We have used the Enrichr analysis tool [45, 46] to identify
the transcription factors (TFs) or histone modifiers which
have been identified by the ChEA database [47] as poten-
tial regulators for significant numbers of genes in each one
of the clusters, sub-clusters, and signatures that we have
considered in this study. The ChEA database of TF regula-
tion was inferred by from various genome-wide ChIP-chip,
ChIP-seq, ChIP-PET, and DamID datasets [47]. The de-
tailed results are shown in Additional file 7, while the TFs
with adjusted combined scores (CS) exceeding 5.0 are
listed in Table 6.
The TF with the most enriched targets in C1 was
found to be MYC, which are also significantly
enriched in both of C1’s sub-clusters. MYC is an onco-
gene encoding a transcription factor which selectively
amplifies genes that contribute to cell growth and pro-
liferation [48]. In normal cells, MYC is only activated
if both sufficient nutrients and growth signals were
available, and is deactivated by active checkpoints or
differentiation. In contrast, abnormal activation of
MYC was seen in cancerous cells leading to uncon-
straint growth and proliferation while ignoring check-
points [48]. These known facts about MYC highly
agree with the biological processes and pathways
enriched in C1, C1a, and C1b, which are mainly re-
lated to cellular growth and proliferation.
In C2the solo significant player is HIF1A, which needs
no further justification. However, C2a is not as signifi-
cantly enriched with the targets of HIF1A as its parent
cluster and two sibling sub-clusters do. This is consist-
ent with the fact that it is not correlated with the
hypoxia-response subset C2b in clinical datasets. None-
theless, the top TFs in C2a are HIF1A, VDR, KDM5B,
and FOXM1 with the respective adjusted CS values of
3.1, 3.1, 3.0, and 3.0. Notably, VDR and KDM5B appear
in either or both of the C1 sub-clusters, either with a
greater value than the threshold or just under it. These
two TFs do not appear in the other two C2 sub-clusters
(C2b and C2c) with any adjusted CS values close to
significant.
Table 6 TFs with significant enrichment in the clusters C1 and C2 as well as their sub-clusters
Cluster TF Adjusted CSa Number of genes Cluster TF Adjusted CSa Number of genes
C1 504 C2 598
MYC 7.9 217 HIF1A 9.4 70
EKLF 7.5 118 C2a 204
JARID1A 6.7 146 C2b 88
ETS1 5.9 115 HIF1A 9.7 16
C1a 116 C2c 168
KDM5B 8.1 70 HIF1A 9.2 24
MYC 6.7 58 51-gene sig.b 51
C1b 273 HIF1A 17.2 17
MYC 10.1 125 20-gene sig.b 20
EKLF 9.0 77 HIF1A 10.1 8




aThe adjusted combined score (CS) calculation is detailed in Additional file 7 where the complete Table is. Only TFs with adjusted CS higher than the threshold of
5.0 are included here
bThe 51-gene and the 20-gene signatures are hypoxia-induced signatures identified in [5] and [24] respectively
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Sub-clusters of hypoxia co-regulated genes are associated
with poor prognosis of tumours and are correlated with
estrogen receptor status
We have investigated the prognostic significance, mea-
sured by hazard ratios (HR), and the relation with estro-
gen (ER) of the sub-clusters of C1 and C2 in the five
clinical datasets listed in Table 5 which have overall sur-
vival (OS) and ER status information. In order to com-
pare our sub-clusters with the state-of-the-art hypoxia
signatures, we have also applied the same analysis to a
signature of 51 genes previously developed using large
meta-analysis of multiple datasets from different cancers
[5], which was shown to be more robust than other hyp-
oxia signatures [6], and to the consensus group of 20
genes recently compiled as the most frequently appear-
ing genes across 32 different hypoxia signatures [24].
We shall refer to these two signatures hereinafter as the
51-gene signature and the 20-gene signature.
C2 has significant overlaps with the 51-gene and the 20-
gene signatures, as it includes 19 and 12 of their genes,
respectively. On the other hand, C1 does not have any
significant overlaps with them. This is expected as C1 is
down-regulated while the 51- and 20-gene signatures are
upregulated under hypoxia. Looking into the sub-clusters of
C2, C2b (88 genes) has the largest overlap with those two
signatures as it includes 6 and 4 of their genes, respectively.
Figure 7 shows the survival curves of the sub-clusters
C1a and C1b as well as the 51-gene signature. The
Figure shows their hazard ratios (HR) and the associ-
ated p-values as estimated by Cox proportional hazards
regression based on the patients’ overall survival time
(OS). Entries with p-values smaller than 0.05 are con-
sidered significant and are marked with a boldface
green font in this Figure. Indeed, higher HR values
(HR > 1.0) indicate bad prognosis while lower HR
values (HR < 1.0) indicate good prognosis. The clusters
or signatures which have significant HR values consist-
ently over all five clinical datasets are C1a (116 genes)
and the 51-gene signature; both suggest bad prognosis
(HR > 1.0). Moreover, C1b also shows significant bad
prognostic values, but in three datasets only. The rest
of the sub-clusters/signatures do not show significant
p-values in more than a single dataset, and their sur-
vival curves are shown in Additional file 8.
As the upregulation of both C1a and the 51-gene
signature in clinical data indicate bad prognosis, we have
calculated HR values for a combined signature com-
posed of both of them. This combined signature’s
survival curves and HR values are shown in Fig. 8. It is
clear in this Figure that the combined signature shows
higher HR values and more significant p-values than
each one of the two signatures separately in each one of
the five datasets. This indicates that the co-upregulation
of both of those hypoxia-induced genes and those MYC
targets is a stronger indication of bad prognosis than
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Fig. 7 Survival curves for sub-clusters and signatures in clinical datasets. Survival curves for the sub-clusters C1a and C1b, as well as the 51-gene
signature based on the five clinical datasets TCGA, GSE2034, GSE3494, METABRIC-disc, and METABRIC-val. In each sub-plot, the vertical axis represents
the survival rate (probability of survival) while the horizontal axis represents time in years. The hazard ratios (HR) and the associated p-values are shown
on the plots while highlighting those with significant p-values (<0.05) with boldface green font. Additional file 8 shows a complete version of this
Figure including all other sub-clusters/signatures (C2a, C2b, C2c, and 20-gene). None of these other sub-clusters/signatures shows significant p-values
in more than one out of five datasets
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We further investigated this prognostic power by plot-
ting the receiver operating characteristic (ROC) curves of
true positives (TP) versus false positives (FP) for C1a and
the 51-gene signature as well as their combination (Fig. 9).
It is clear that the signatures C1a and 51-gene have
consistent significance of prognostic power over the five
datasets when considered individually (p-value <0.05).
However, neither outperforms the other in all of the data-
sets. Interestingly, when they are combined, their prognos-
tic power clearly improves, and either outperforms both
individual signatures or is very close to the better one
amongst them in all five datasets. Again, this shows that
the conjoint up-regulation of these two subsets of genes in
clinical tumours, which are regulated oppositely under
hypoxia in vitro, is a strong indication of poor prognosis.
Table 7 shows expression fold-changes of the sub-
clusters and signatures in ER+ samples versus ER− samples
(ER+/ER−) as estimated by analysis of variance (ANOVA).
All sub-clusters of C1 and C2 and the 51-gene signature
have significant fold-changes except for C2c. Interestingly,
C2a goes up in ER+ samples (fold-change >1), while C1a,
C1b, C2b, and the 51-gene signature go down (fold-
change <1). The fact that C2b and the 51-gene signature
do so, confirms ER+ being less hypoxic than ER− tumours
as discussed previously.
We then investigated if the OS times of the samples
with the ER+ status and the ones with the ER− status differ
significantly by applying ANOVA analysis, which is the
type of statistical analysis to assess if two groups of values
are significantly different. Results showed that there was
no significant differential OS time between ER+ and ER−
samples in three out of five clinical datasets (p-values: 0.42
in TCGA, 0.20 in GSE2034, 0.26 in GSE3494, 6.1 × 10−4
in METABRIC-disc, and 2.6 × 10−6 in METABRIC-val).
Pairwise Spearman’s correlation amongst the sum-
marised expression profiles of the sub-clusters and the
signatures in the six clinical datasets has been calculated
(Additional file 9). The summarised expression profile of
a signature or a cluster is represented by its hypoxia
scores (HS) as detailed in Methods. The results are sum-
marised in Fig. 10. Interestingly, the Figure shows that
the two sub-clusters of C2 (C2a and C2b), which are
consistently correlated in cell line datasets, completely
lose their correlation in all six clinical datasets. On the
other hand, C1b joins C2b in having consistent positive
correlation with the 51-gene signature in each one of the
six datasets (ρ ranging from 0.35 and 0.6; Fig. 10 and
Additional file 9). It was expected for C2b to have such
correlated profiles due to its overlap with the 51-gene
signature, but C1b does not have any significant overlap
with the signature in terms of its gene-content. Indeed,
C1b, C2b, and the 51-gene signature are upregulated in
ER− samples (Table 7). Moreover, C1b and C2a, which
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Fig. 8 Survival curves for a combined signature composed of C1a and the 51-gene signature. The survival curves are based on each one of the












































































Fig. 9 ROC curves for the signatures C1a and 51-gene separately and combined over the five clinical datasets. The combined signature is shown
in a thicker line. Moreover, the area under the curve (AUC) for each of these curves as well as the associated p-values are shown in the legends
below the plots
Abu-Jamous et al. Molecular Cancer  (2017) 16:105 Page 11 of 19
statuses, are also consistently negatively correlated in
expression over the six datasets (ρ from −0.45 to −0.85;
Fig. 10 and Additional file 9).
Comparison of UNCLES with the iCluster method
The iCluster method has become a commonly used
method for clustering in cancer research, especially for
multiple datasets [25, 49]. Therefore, we have compared
our method with it. We have applied iCluster to the
same set of 16 cell-line datasets using its default parame-
ters. The iCluster method requires pre-setting the num-
ber of clusters (K) to which the genes should be
partitioned, so we applied it many times with K values
ranging from 2 to 54. The details of the application of
the method are provided in Additional file 10.
One key difference between UNCLES and iCluster is
that the iCluster method forces all of the 15,588 input
genes to be included in one of its output clusters. For
example, at K = 26, iCluster partitions the 15,588 genes
into 26 clusters without filtering out any gene. This fact
is important to remember while comparing the results
of the two methods. Figure 11 shows the distribution of
the genes included in our clusters C1 (504 genes) and
C2 (598 genes) over the clusters generated by iCluster at
four different K values, 2, 26, 31, and 54. Two major
observations can be seen here; the first one is that the
contents of our C1 and C2 clusters are always included
in different iCluster clusters at any given K value; in
other words, if one of the iCluster clusters includes a
significant number of C1 genes, it does not include a
significant number of C2 genes at the same time (no sin-
gle point on the horizontal axes in Fig. 11 shows large
upwards and downwards bins at the same time). This
validates our UNCLES clusters as it is an evidence of
Table 7 Fold-changes of expression of signatures in relation to ER (ER+/ER−) and their associated p-values between parentheses
Sub-cluster/signature TCGA GSE2034 GSE3494 METABRIC-disc METABRIC-val
C1a 0.88 (0.006) 0.94 (0.033) 0.94 (7.5 × 10−4) 0.95 (1.1 × 10−4) 0.94 (1.5 × 10−6)
C1b 0.77 (8.8 × 10−18) 0.89 (1.6 × 10−11) 0.91 (4.9 × 10−16) 0.91 (2.0 × 10−29) 0.90 (1.3 × 10−38)
C2a 1.28 (8.3 × 10−13) 1.14 (2.1 × 10−10) 1.10 (1.9 × 10−12) 1.08 (1.3 × 10−17) 1.09 (4.1 × 10−20)
C2b 0.56 (4.3 × 10−28) 0.74 (1.0 × 10−23) 0.86 (1.3 × 10−14) 0.79 (1.9 × 10−59) 0.81 (4.4 × 10−51)
C2c 1.01 (0.78) 1.01 (0.53) 1.02 (0.16) 1.02 (0.025) 1.04 (5.4 × 10−4)
51-gene signature 0.63 (1.4 × 10−10) 0.76 (1.8 × 10−12) 0.86 (7.0 × 10−9) 0.80 (2.0 × 10−30) 0.81 (1.7 × 10−26)
20-gene signature 0.71 (0.003) 0.81 (8.6 × 10−4) 0.96 (0.35) 0.86 (3.4 × 10−7) 0.90 (2.6 × 10−4)






Fig. 10 Expression relations amongst the sub-clusters and signatures in cell line and clinical datasets. Part a shows that in the 16 cell-line datasets,
when hypoxia occurs, C1 sub-clusters are repressed while C2 sub-clusters are up-regulated. The 51-gene and the 20-gene signatures were previously
established as signatures of hypoxia, and they are indeed up-regulated under hypoxia. Parts b to (g) show the gene expression relations amongst the
different sub-clusters or signatures in each one of the six considered clinical datasets. Also, the ER status is included where its information is available.
For example, b shows that in the TCGA dataset, when ER is down (negative), C2a genes go down in expression, while the expression of the genes in
C1b, C2b, and the 51-gene and 20-gene signatures go up
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their high separability. The second observation is that as
iCluster includes the entire input set of genes (15,588)
into clusters, it does not have a mechanism to select few
clusters with the highest priority, and therefore does not
imply filtering. For instance, at K = 2, iCluster partitions
the 15,588 input genes into two clusters with 7317 and
8217 genes, respectively. Although each one of these
two iCluster clusters exclusively includes one of our two
UNCLES clusters entirely (Fig. 11 (A)), those two iClus-
ter clusters are relatively giant and are much less specific
than our UNCLES clusters.
Discussion
We have demonstrated that poor prognosis can be pre-
dicted in breast cancer clinical samples by the conjoint
up-regulation of two distinct subsets of genes which are
rather observed to be oppositely regulated under hyp-
oxia in sixteen in vitro breast cancer cell-line datasets.
One of these two subsets of genes is upregulated under
hypoxia in cell-lines and is enriched with HIF targets
that have roles in response to hypoxia. In contrast, the
other subset of genes is down-regulated under hypoxia
in cell-lines and is enriched with MYC targets that are
involved in various growth processes. Interestingly, the
gene expression values of these two subsets are positively
correlated in six examined clinical datasets, predicting
poor prognosis when up-regulated, and demonstrating a
clear case of deep disagreement between cell-lines and
clinical data.
To be able to generalise our results within the context
of breast cancer tissues under hypoxia, the 16 cell-line
datasets that we analysed were chosen from that context
but from various cell-lines and biological conditions
(Table 1), and this is feasible due to the capability of the
developed computational methods herein. Moreover, the
microarray platforms of these datasets vary widely in
terms of the manufacturer (e.g. Affymetrix and Illumina)
and the actual model. This allows for the inaccuracies
and missing data which may exist in some datasets to be
overcome by the majority of the other datasets. In other
words, although every platform has its own inherent
imperfections, they are reduced by using the entirety of
the 16 datasets.
The core results have been obtained by applying a
clustering approach which we have developed recently
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Fig. 11 A comparison between the results of UNCLES and the results of iCluster. The distribution of the 504 genes in C1 and the 598 genes in
C2 over the clusters generated by iCluster at a K = 2, b K = 26, c K = 31, and d K = 54. The horizontal axis in each plot represents the K clusters
generated by iCluster in that case. For each iCluster cluster, i.e. at each point of the horizontal axes, two bins are shown, one upwards and one
downwards. The upward bin reflects the number of genes from our C1 cluster that are included in that corresponding iCluster cluster, while the
downward bin reflects the number of genes from our C2 cluster therein. A key observation is that none of the iCluster clusters shows large bins
in both directions
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employed to identify cohorts of co-regulated genes from
collections of many datasets generated under diverse
conditions. Comparisons with the commonly used iClus-
ter method have revealed the unique ability of our ap-
proach to analyse integrated data at such a scale.
What causes this mismatch between in vitro cell-lines and
clinical data?
The mismatched relation between hypoxia-repressed
genes (C1a) and hypoxia-induced genes (C2b and the 51-
gene sub-cluster) in cell-line data versus clinical data may
be due to their transcriptional regulators. Results showed
that MYC seems to be the main activator of C1 and its
sub-clusters (C1a and C1b) while HIF1A is the main acti-
vator of C2 and two of its sub-clusters (C2b and C2c)
(Table 6). HIF1A and MYC interplaying is well-known in
cancers [10]; under hypoxia, HIF1A represses MYC
through different suggested ways, such as activating MXI-
1, which is an antagonist of MYC with regards to mito-
chondrial biogenesis [50, 51], or by competing with MYC
in binding directly to MAX, without which MYC does not
carry out its function [48], or by binding to Sp1 to result
in the displacement of MYC from Sp1 complexes and
consequently decreased MYC activity [52]. These facts
well justify the consistent anti-correlation observed be-
tween these two groups of genes in cell lines.
In contrast, and in all six clinical datasets, either or
both sub-clusters of genes activated by MYC (C1a and
C1b) show positive correlation with those activated by
HIF1A (mainly C2b) (Fig. 10 (b-g)). Apparently, in vivo
further selection, maybe through mutations of genes like
TP53 and HER2, or other micro-environmental or epigen-
etic factors, overcomes the suppression effect of hypoxia
mediated by HIF on these MYC-regulated growth genes.
The expression of MYC itself is significantly upregulated
in ER− samples versus ER+ samples in four out of five clin-
ical datasets with ER information (p-values of 6 × 10−8,
5 × 10−4, 0.8, 1 × 10−3, and 9 × 10−9 respectively). Indeed,
HIF1A is significantly upregulated in ER− samples in all
five datasets (p-values of 5 × 10−17, 5 × 10−7, 5 × 10−4,
5 × 10−20, and 9 × 10−24 respectively). Overexpression of
MYC was shown to overcome the competition of HIF1A
with it over MAX, and thus overexpressed MYC maintain
stable MYC-MAX heterodimers despite the presence of
HIF1A [53], and is associated with poor outcome [54].
Nonetheless, what causes MYC to be overexpressed in tu-
mours and not in cell lines? Also, MYC does not seem to
be overexpressed in ER− tumours in one of the clinical
datasets, yet its predicted targets involved in growth and
proliferation are upregulated. Is there an alternative regu-
latory machinery which upregulates such a group of genes
despite the presence of HIF1A and the absence of MYC?
For instance, HIF2A (EPAS1) was shown to have a pro-
moting effect on MYC as opposed to HIF1A, and it was
suggested that those two HIF factors are likely to neg-
ate each other’s effect on MYC when both are present
[10, 53]. However, as seen in the expression of C1 and
C2 in the dataset D13, knocking down HIF2A in the
MCF7 cell line showed know difference in the expres-
sion of either C1 or C2 compared with wild-type cells,
but knocking down HIF1A did down-regulate C2 and
up-regulate C1, and that was similar between knocking
down HIF1A only and a double-knocking down of both
factors (Fig. 2 and Additional file 2). Also, there is no
significant upregulation of HIF2A in ER− samples ver-
sus ER+ in any of the clinical datasets (p-values always
higher than 0.1).
Such results further demonstrate, as discussed in pre-
vious studies and reviews [24], that cell lines, despite
their usefulness, do not accurately represent real clinical
tumours. We provide the community with new sig-
nificant signatures of hypoxia which are derived from
cell lines, and then mapped to clinical samples to derive
prognostic signatures, namely C2b and the more in-
teresting C1a. We also provide such a thorough com-
parison between the gene expression of different groups
of genes under clinical or cell line datasets, which may
lead to a better understanding of the factors influencing
the differences between the two systems.
Speculations regarding novel association of genes with
hypoxia response
A few genes with unknown or poorly understood func-
tions have been found in the clusters C1 and C2. The
most notable ones are RSBN1 (chromosomal location
1p13.2) and KIAA0195 (aka TMEM94; chromosomal
location 17q25.1), which are induced under hypoxia, and
they have been identified as potential HIF targets by 7 or
5 different HIF target lists respectively (Table 4).
Only one study focused on RSBN1 gene or on any of
its homologues [55]. This study suggested that murine
RSBN1 may have a transcriptional regulatory role in
haploid germ of male mice as it specifically localise in
the nucleus at stages VII-VIII of murine spermatogenesis
[55]. Interestingly, scrutiny of Takahashi and colleagues’
experiments shows that they investigated RSBN1’s ex-
pression in the brain, heart, intestine, kidney, liver, lung,
muscle, ovary, spleen, and testis of male mice, to con-
clude that it is only expressed in the testis [55]. In other
words, expression of RSBN1 in murine female breast
tissues was not investigated, and it may well be regulated
by HIF as all seven lists include it, it may be expressed
in breast tissues, and may have a role in response to
hypoxia in breast cancer consequently.
Few genome-wide studies identified interactions be-
tween KIAA0195, or one of its homologues, and some
other gene products, such as the kinase CDK5 [56–58],
ubiquitin C (UBC) [59, 60], and the Drosophila’s CG9099
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protein [61]. To find KIAA0195 consistently co-expressed
with many other HIF targets in our study and in five out
of seven lists of potential HIF targets indicates that this
poorly understood gene may be a genuine target of HIF
and may also have a role in response to hypoxia.
Conclusions
Poor prognosis can be predicted by the conjoint up-
regulation of two subsets of genes in breast tumours,
which we identified in this study. The first subset is
enriched with MYC targets participating in various
growth-related processes, while the second subset is
enriched with targets of the hypoxia-induced factor
(HIF) and is expected to participate in response to hyp-
oxia. The HIF-targets subset includes genes that are
consistently co-expressed in sixteen different breast can-
cer cell-line datasets generated from conditions related
to hypoxia. As expected, it shows up-regulation exclu-
sively under hypoxic conditions in all of these cell-lines,
which agrees with the literature associating hypoxia with
bad prognosis. Strikingly, the MYC-targets growth-
related subset shows an opposite profile in all tested
cell-line datasets, where its genes are always repressed
by hypoxia. This is despite the fact that its up-regulation
in tumours indicates poor prognosis. The repression of
growth-related genes under hypoxia agrees well with ex-
pectations, which we observe in cell-lines (in vitro).
However, the association of their up-regulation in tu-
mours (in vivo) with poor prognosis is an interesting
finding. In fact, we showed that the conjoint in vivo up-
regulation of both subsets combined with an existing
state-of-the-art hypoxia signature is as strong in predict-
ing bad tumour outcomes as that state-of-the-art signa-
ture and potentially stronger.
These results were found by analysing six clinical data-
sets after the application of the UNCLES method, with
its novel and important extension that we introduced in
this study, to sixteen different genome-wide gene expres-
sion datasets of breast cancer cell-lines. These datasets
were generated by different groups, using different plat-
forms, and under different conditions related to hypoxia.
This method, which is publically available as part of the
Clust python package [27, 62], can be applied to other
sets of gene expression datasets from other areas in
order to find those subsets of genes which are consist-
ently co-expressed over all of them. The uniqueness of
the ability to perform this task fruitfully at a genome-
wide scale as such has been demonstrated by comparisons
with iCluster, which is a relevant state-of-the-art method.
Methods
Uncles
The unification of clustering results from multiple data-
sets using external specifications (UNCLES) has two
types, A and B. Type A mines a set of datasets for the
subsets of genes which are consistently co-expressed in
all of them. On the other hand, type B identifies the
subsets of genes which are consistently co-expressed in
a subset of datasets while being poorly co-expressed in
another subset of datasets. Here, we adopt UNCLES type
A, which is applied by applying the binarisation of
consensus partition matrices (Bi_CoPaM) method. The Bi-
CoPaM method consists of four main steps [27, 63, 64]:
1. Generation of many partitions for the same set of
genes by applying C different clustering methods
over the expression profiles of these genes from L
different microarray datasets. As each of these C
methods is applied independently to each one of the
L microarray datasets, this step generates R = C × L
different partitions. All of these partitions should
have the same number of clusters (K).
2. Relabelling the R partitions. The clusters within each
partition are permuted such that the ith cluster from
one partition corresponds to the ith cluster from
each one of the other partitions. This is essential
because, due to the unsupervised nature of
clustering, different partitions are not guaranteed to
have this alignment of their clusters. We adopt the
min-min relabelling technique [26] here because it
aims at giving the fittest clusters a higher priority
to be properly matched even if the poorer clusters
are improperly matched. This is in contrast to the
min-max technique [27] which aims at giving poorer
clusters a chance to be fairly matched even if the
compensation was to reduce the matching quality
of the fittest clusters. The latter is better when all of
the clusters are of interest, while the former is more
suitable for the aim of our study, in which we prefer
to optimise the fittest clusters and eliminate the
remaining clusters from the final result.
3. Generation of the fuzzy consensus partition matrix
(CoPaM) by element-by-element averaging of the
relabelled partitions. This fuzzy CoPaM assigns each
gene to each one of the K different clusters with a
fuzzy value ranging from zero (does not belong) to
unity (perfectly belongs).
4. Binarization of the CoPaM by one or more of the
six tuneable binarization techniques proposed in
[27]. Here we adopt the difference threshold
binarisation (DTB) technique, which assigns a gene
to the cluster in which it has the highest fuzzy
membership value if, and only if, the fuzzy
membership value of that gene in any of the other
clusters is lower than that highest value at least by
the value of the tuning parameter δ. In other words,
if two or more clusters compete over a given gene
with close fuzzy membership values, the gene is not
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considered distinctly belonging to a single specific
cluster, and is, consequently, not assigned to any of
them. The tightness of the clusters is therefore
controlled by the value of δ, which ranges from zero
(loosest) to unity (most stringent).
The UNCLES method is implemented as part of the
open-source Python package “Clust” available on https://
github.com/BaselAbujamous/clust [62].
Extension of UNCLES
The UNCLES method, as was proposed in [26], requires
that all of the datasets measure the expression profiles of
identical sets of genes (Fig. 12 (A)). We propose a novel
extension of the UNCLES method here to allow it to
analyse multiple datasets where genes are included at
least in L* out of the given L datasets. In this case, the
individual clustering methods (e.g. k-means, SOMS, etc.)
are applied to each dataset individually based on the
genes which are represented by that dataset only. After
that, when the individual results are combined by aver-
aging element-by-element to produce the fuzzy CoPaM
matrix, gene membership values are averaged only based
on, and weighted by, the datasets which include that
gene, even if not all of them.
This extension of the UNCLES method is implemented
as part of the open-source Python package “Clust” avail-
able on https://github.com/BaselAbujamous/clust [62].
M-N scatter plots technique
The UNCLES method requires a fixed number of clusters
(K) to be set as well as the tuning parameter δ. However,
the best values of K and δ may not be easily set manually.
The M-N scatter plots technique addresses this issue by
selecting the best clusters of the results of the application
of UNCLES multiple times, each with a different K value
and with varying δ values. All of the individual clusters
from these different results of UNCLES are scattered on a
2-D plot. Each point on the plot represents one cluster,
the horizontal axis represents the dispersion of the cluster
measured by a modified version of the mean-square error
(MSE) metric, and the vertical axis represents the loga-
rithm of the size of the cluster, i.e. the logarithm of the
number of genes included in the cluster.
Aiming at minimising the dispersion of the clusters
(horizontal axis) while maximising their sizes (vertical
axis), the cluster which is represented by closest point to
the top-left corner of the plot is selected as the best
cluster. This solves the problem of merely minimising the
dispersion, as the dispersion of the trivially small clusters
which include one or few genes is usually the minimum.
In contrast, the M-N scatter plots favours larger clusters
which maintain as low dispersion as possible.
It is likely that many of the repetitions of UNCLES
have produced clusters with similar contents. Therefore,
after selecting the top-left cluster in the M-N plot, all of
those clusters with overlapping contents are removed
from the plot. Out of the remaining clusters in the plot,
the one which is closest to the top-left corner is selected
as the second best cluster. The same steps are repeated
until the M-N plots are empty or until the researcher is
satisfied with the top few clusters obtained.
As can be seen, M-N plots do not select a whole parti-
tion and does not select the best K value or δ values. It
rather selects the best clusters ordered in quality, which
might have been generated by different K or δ values.
The M-N scatter plots technique is implemented as
part of the open-source Python package “Clust” available
on https://github.com/BaselAbujamous/clust [62].
Data pre-processing
Prior to clustering, the one-colour datasets were normal-
ised by quantile normalisation [65]. Then each gene’s
expression profile was shifted and scaled to be zero-
mean and unity standard deviation. The log-ratios of the
two-colour datasets were zero-centred by subtracting
genes’ log-ratios’ mean values [66]. In case of having
multiple replicates per condition, the median value was
taken. In the case of having multiple probes in the same
dataset representing the same gene, the representative
probe was considered as the one with the maximum
coefficient of variation while at least a quarter of its
samples exceed the first quartile of expression values in
Fig. 12 A demonstration of the difference between the original
UNCLES and the extended one. a Original UNCLES: all datasets must
have identical sets of genes. b Extended UNCLES: some datasets
may miss some of the input set of genes. Both a and b allow
datasets to have different numbers of samples
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that dataset. If none of the probes representing a gene
exceeds that quartile, the one with highest coefficient of
variation of all of its probes was considered.
Statistical analysis of clinical datasets
Given a clinical dataset, a single representative probe-set
is first selected for each gene which has multiple probe-
sets. This is done by taking the most variable probe-set, as
measured by covariance, out of the probe-sets exceeding
the 25th percentile expression in at least 25% of the sam-
ples. If no probe-set for that particular gene exceeds the
aforementioned threshold, the most variable probe-set
amongst all of the genes’ probe-sets is selected. The data-
set is thereafter normalised by quantile normalisation.
To test the prognostic capability of a signature given a
normalised dataset, the signature is first summarised by
taking the median expression value of its genes at each
sample. The median values are ranked over the samples
and then scaled to the range of 0.0 to 1.0. Those [0.0, 1.0]
values are called the hypoxia scores (HS) of the signature
over each one of the samples. The HS values are submit-
ted to Cox proportional hazards regression analysis to ob-
tain their hazard ratios (HR) and the associated p-values.
If the estrogen (ER) status of the samples is provided
with the clinical dataset, analysis of variance (ANOVA)
is performed for each gene in the dataset in order to
identify if it is differentially expressed between ER+ and
ER- samples. A p-value and the fold-changes are there-
fore associated with each gene. The average of the ex-
pression values of each gene was shifted to zero and the
standard deviation was scaled to unity before submission
to ANOVA analysis. The negative logarithm of those
ANOVA p-values followed an approximately lognormal
distribution, while the fold-changes followed, as they
were, a lognormal distribution. Therefore, to test if the
genes of a given signature have significantly lower
ANOVA p-values or higher fold-changes over the ER
variable compared with the rest of the genome, another
ANOVA analysis was adopted over the logarithm of the
negative logarithm of the p-values, and over the loga-
rithm of the fold-changes.
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